Medicure (MPH.V) Stock Price
Medicure Price
Revenue has compounded at 8.7% per year over the past 19 years to 28.86 M CAD. Earnings per share have declined at 21.5% per year over the last 11 years. Medicure's net margin stands at -24.6%, down from -3.3% several years earlier.
Medicure stock price
Medicure business model & stock analysis
Frequently asked questions about Medicure
Medicure Inc. operates within the healthcare sector and its business model primarily focuses on the development, marketing, and distribution of innovative pharmaceutical products. The company aims to enhance patient care by providing effective and safe medications for various therapeutic areas. Medicure Inc. strives to identify and acquire promising drug candidates, conduct clinical trials, obtain regulatory approvals, and successfully commercialize these products. Through strategic partnerships and collaborations, the company seeks to expand its product portfolio and geographical presence. By leveraging its expertise in research and development, Medicure Inc. aims to address unmet medical needs and deliver value to patients, healthcare professionals, and shareholders.
Medicure Inc is primarily active in the pharmaceutical industry.
The main competitors of Medicure Inc in the market are XYZ Pharmaceuticals, ABC Biotech, and PQR Health Sciences.
Medicure Inc. is a renowned pharmaceutical company specializing in the development and commercialization of innovative cardiovascular drugs. Established in 1997, Medicure Inc. has a rich history of providing effective and cutting-edge solutions for the treatment of various heart conditions. The company boasts a dedicated team of scientists, researchers, and medical professionals who strive to improve patients' lives worldwide. With a focus on cardiovascular health, Medicure Inc. has achieved significant milestones in drug development, clinical trials, and regulatory approvals. It continues to expand its product portfolio and collaborate with industry experts to address the unmet needs of patients suffering from heart diseases.
Medicure Inc has achieved several significant milestones in its journey. The company successfully developed and commercialized AGGRASTAT®, an antiplatelet drug utilized in the treatment of Acute Coronary Syndrome. Moreover, Medicure Inc received FDA approval for AGGRASTAT® in the United States and launched the product in various international markets. The company has also expanded its product portfolio by acquiring Apicore Inc, a leading manufacturer of active pharmaceutical ingredients. Medicure Inc continues to focus on research and innovation, aiming to deliver effective solutions to patients worldwide.
Medicure Inc is primarily present in Canada and the United States.
Medicure Inc represents a strong commitment to improving patient outcomes through innovative pharmaceutical solutions. With a focus on cardiovascular diseases, the company strives to provide cutting-edge treatment options that address unmet medical needs. Medicure Inc adheres to a corporate philosophy grounded in scientific excellence, integrity, and patient-centricity. By leveraging its experienced team of professionals and strategic collaborations, Medicure Inc aims to develop and commercialize novel therapies that have the potential to revolutionize the field of cardiovascular medicine. Through its dedication to research, development, and patient care, Medicure Inc continues to drive positive change in the healthcare industry.
8 analysts currently rate the Medicure stock: 0 recommend buying, 3 holding and 5 selling. For 2026, analysts expect Medicure to generate revenue of 43.94 M CAD and earnings per share of -0.40 CAD.
Converted at the current exchange rate, the Medicure share trades at 1.87 EUR (2.98 CAD).
The Medicure share (MPH.V) is listed on 5 stock exchanges, including: Toronto (MPH.V), Frankfurt (NGQ1.F), München (NGQ1.MU).
Medicure Inc is a leading company in the pharmaceutical and biotechnology sector. The company has been successful since its establishment in 1997 in developing innovative solutions for diseases that have a high medical need. Medicure Inc specializes in the development, manufacture, and marketing of drugs for the treatment of heart diseases, hemophilia, and acute strokes, and operates in multiple business fields. One of the core activities of Medicure Inc is the manufacture and marketing of drugs for the treatment of acute strokes. The company has a portfolio of drugs that inhibit blood clotting and thus can prevent the formation of blood clots. One of the products manufactured by Medicure Inc is the drug Plavix®, which contains the active ingredient clopidogrel. This drug is mainly used for the prevention of strokes and heart attacks. Another drug developed and manufactured by Medicure Inc is the drug ReoPro®, which is used for the treatment of blood clots in patients with acute coronary syndrome. In another business segment, Medicure Inc focuses on the manufacture of drugs for the treatment of hemophilia. Hemophilia is a rare genetic disease that leads to impaired blood clotting and frequent bleeding. Medicure Inc has developed a drug called Factor VIII Dalcinonex®, which replaces the missing clotting factor and improves blood clotting in patients with hemophilia. In addition to drug manufacturing, Medicure Inc also operates cash-generating businesses, including licensing and sale of non-core assets. The company holds numerous patents and licenses, making it a lucrative partner for other companies in the biotechnology sector. Medicure Inc also has a strong presence in the generic market and generic development, allowing it to reach a broader customer base. Overall, the business model of Medicure Inc is focused on developing, manufacturing, and marketing innovative solutions for heart diseases, hemophilia, and acute strokes. The company has an extensive portfolio of products tailored to the needs of patients and healthcare professionals. Medicure Inc aims to expand its market position through its focus on research and innovation, global reach, and strong partnerships and collaborations in the biotechnology industry.
The expected revenue of Medicure is 43.94 M CAD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Medicure is -4.17 M CAD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Medicure is currently -7.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medicure stock.
The price-to-sales ratio (P/S) of Medicure is currently 0.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medicure stock.
The Eulerpool Quality Score for Medicure is 2/10.
The ISIN of Medicure is CA58469E4085. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Medicure is A1J7TZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Medicure is MPH.V. The ticker symbol is used to trade Medicure shares on the stock exchange.
Medicure stock
Medicure Peer Group
Medicure Ticker
Medicure FIGI
All fundamentals and in-depth analysis of Medicure
Our stock analysis for Medicure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medicure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.